Potential Applications of Endo-B-N-Acetylglucosaminidases From Bifidobacterium longum Subspecies infantis in Designing Value-Added, Next-Generation Infant Formulas

Authors

Hatice Duman, Çanakkale Onsekiz Mart University
Merve Kaplan, Çanakkale Onsekiz Mart University
Aysenur Arslan, Çanakkale Onsekiz Mart University
Arif Sercan Sahutoglu, Çanakkale Onsekiz Mart University
Haci Mehmet Kayili, Karabuk University
Steven A. Frese, University of Nebraska-Lincoln; University of Nevada RenoFollow
Sercan Karav, Canakkale Onsekiz Mart University, TurkeyFollow

Document Type

Article

Date of this Version

2021

Citation

Duman H, Kaplan M, Arslan A, Sahutoglu AS, Kayili HM, Frese SA and Karav S (2021) Potential Applications of Endo-B-N-Acetylglucosaminidases From Bifidobacterium longum Subspecies infantis in Designing Value-Added, Next-Generation Infant Formulas. Front. Nutr. 8:646275. doi: 10.3389/fnut.2021.646275

Comments

This article was submitted to Nutrition and Microbes, a section of the journal Frontiers in Nutrition

Abstract

Human milk is the optimal source of infant nutrition. Among many other health benefits, human milk can stimulate the development of a Bifidobacterium-rich microbiome through human milk oligosaccharides (HMOs). In recent years, the development of novel formulas has placed particular focus on incorporating some of the beneficial functional properties of human milk. These include adding specific glycans aimed to selectively stimulate the growth of Bifidobacterium. However, the bifidogenicity of human milk remains unparalleled. Dietary N-glycans are carbohydrate structures conjugated to a wide variety of glycoproteins. These glycans have a remarkable structural similarity to HMOs and, when released, show a strong bifidogenic effect. This review discusses the biocatalytic potential of the endo-B-N-acetylglucosaminidase enzyme (EndoBI-1) from Bifidobacterium longum subspecies infantis (B. infantis), in releasing N-glycans inherently present in infant formula as means to increase the bifidogenicity of infant formula. Finally, the potential implications for protein deglycosylation with EndoBI-1 in the development of value added, next-generation formulas are discussed from a technical perspective.